SlideShare a Scribd company logo
1 of 1
The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B
infections from India, Uganda and South Africa

            Emmanuel Ngabirano,Portsmouth, S.; Napolitano, LA.; Eng, S.; Greenacre,
 Authors:
            A.; Kambugu, A.; Wood, R.; Badal-Faesen, S.
  Year:     2012
 Journal: J Int AIDS Soc.                                        Volume:           15
 Number: 1                                                        Pages:           2
 Month: July

  Abstract:
BACKGROUND: The introduction of C-C chemokine receptor type-5 (CCR5) antagonists as
antiretroviral therapy has led to the need to study HIV co-receptor tropism in different HIV-1
subtypes and geographical locations. This study was undertaken to evaluate HIV-1 co-
receptor tropism in the developing world where non-B subtypes predominate, in order to
assess the therapeutic and prophylactic potential of CCR5 antagonists in these regions.
METHODS: HIV-1-infected patients were recruited into this prospective, cross-sectional,
epidemiologic study from HIV clinics in South Africa, Uganda and India. Patients were
infected with subtypes C (South Africa, India) or A or D (Uganda). HIV-1 subtype and co-
receptor tropism were determined and analyzed with disease characteristics, including viral
load and CD4(+) and CD8(+) T cell counts. RESULTS: CCR5-tropic (R5) HIV-1 was
detected in 96% of treatment-naïve (TN) and treatment-experienced (TE) patients in India,
71% of TE South African patients, and 86% (subtype A/A1) and 71% (subtype D) of TN and
TE Ugandan patients. Dual/mixed-tropic HIV-1 was found in 4% of Indian, 25% of South
African and 13% (subtype A/A1) and 29% (subtype D) of Ugandan patients. Prior
antiretroviral treatment was associated with decreased R5 tropism; however, this decrease was
less in subtype C from India (TE: 94%, TN: 97%) than in subtypes A (TE: 59%; TN: 91%)
and D (TE: 30%; TN: 79%). R5 virus infection in all three subtypes correlated with higher
CD4(+) count. CONCLUSIONS: R5 HIV-1 was predominant in TN individuals with HIV-1
subtypes C, A, and D and TE individuals with subtypes C and A. Higher CD4(+) count
correlated with R5 prevalence, while treatment experience was associated with increased non-
R5 infection in all subtypes

More Related Content

What's hot

Professional Presentations and Posters_Syndromic
Professional Presentations and Posters_SyndromicProfessional Presentations and Posters_Syndromic
Professional Presentations and Posters_Syndromic
Anne Jeanette Burke, MS
 
SSC2 Oral Presentation M5724
SSC2 Oral Presentation M5724SSC2 Oral Presentation M5724
SSC2 Oral Presentation M5724
Sze Hao Tan
 
Poster_hepC_EAHP
Poster_hepC_EAHPPoster_hepC_EAHP
Poster_hepC_EAHP
David Dias
 
Immunology and Detection of Acute HIV-1 Infection
Immunology and Detection of Acute HIV-1 InfectionImmunology and Detection of Acute HIV-1 Infection
Immunology and Detection of Acute HIV-1 Infection
Rongpong Plongla
 

What's hot (19)

Dr. Robert Tauxe - Human Health Viewpoint and Setting the Tone for the Antibi...
Dr. Robert Tauxe - Human Health Viewpoint and Setting the Tone for the Antibi...Dr. Robert Tauxe - Human Health Viewpoint and Setting the Tone for the Antibi...
Dr. Robert Tauxe - Human Health Viewpoint and Setting the Tone for the Antibi...
 
Journal Reading Stem Cell dengan HIV (sharon)
Journal Reading Stem Cell dengan HIV (sharon) Journal Reading Stem Cell dengan HIV (sharon)
Journal Reading Stem Cell dengan HIV (sharon)
 
cck-2 gastrin-r-immunodistribution-in-a-solid-pseudopapillary-pancreatic-tumo...
cck-2 gastrin-r-immunodistribution-in-a-solid-pseudopapillary-pancreatic-tumo...cck-2 gastrin-r-immunodistribution-in-a-solid-pseudopapillary-pancreatic-tumo...
cck-2 gastrin-r-immunodistribution-in-a-solid-pseudopapillary-pancreatic-tumo...
 
vit D effect on COVID cytokine storm
vit D effect on COVID cytokine stormvit D effect on COVID cytokine storm
vit D effect on COVID cytokine storm
 
Covid -19 evidence that vitamin d supplementation could reduce risk of corona...
Covid -19 evidence that vitamin d supplementation could reduce risk of corona...Covid -19 evidence that vitamin d supplementation could reduce risk of corona...
Covid -19 evidence that vitamin d supplementation could reduce risk of corona...
 
The misunderstood epidemiological determinants of covid 19, problems and solu...
The misunderstood epidemiological determinants of covid 19, problems and solu...The misunderstood epidemiological determinants of covid 19, problems and solu...
The misunderstood epidemiological determinants of covid 19, problems and solu...
 
Professional Presentations and Posters_Syndromic
Professional Presentations and Posters_SyndromicProfessional Presentations and Posters_Syndromic
Professional Presentations and Posters_Syndromic
 
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...
 
New WHO Phases: Issues Related to the Pandemic of a Novel A(H1N1) Virus
New WHO Phases: Issues Related to the Pandemic of a Novel A(H1N1) VirusNew WHO Phases: Issues Related to the Pandemic of a Novel A(H1N1) Virus
New WHO Phases: Issues Related to the Pandemic of a Novel A(H1N1) Virus
 
Superbug Infection | Dr Jose Poulose
Superbug Infection | Dr Jose PouloseSuperbug Infection | Dr Jose Poulose
Superbug Infection | Dr Jose Poulose
 
The Prevalence of Cytomegalovirus among Eligible Blood Donors in Keffi, Nigeria
The Prevalence of Cytomegalovirus among Eligible Blood Donors in Keffi, NigeriaThe Prevalence of Cytomegalovirus among Eligible Blood Donors in Keffi, Nigeria
The Prevalence of Cytomegalovirus among Eligible Blood Donors in Keffi, Nigeria
 
Hygiene and disease prevention in Allah Dad Khan
Hygiene and disease prevention in  Allah Dad KhanHygiene and disease prevention in  Allah Dad Khan
Hygiene and disease prevention in Allah Dad Khan
 
SSC2 Oral Presentation M5724
SSC2 Oral Presentation M5724SSC2 Oral Presentation M5724
SSC2 Oral Presentation M5724
 
Poster_hepC_EAHP
Poster_hepC_EAHPPoster_hepC_EAHP
Poster_hepC_EAHP
 
19 20 nov2018. visit of prof asit pattnaik from the university of nebraska, l...
19 20 nov2018. visit of prof asit pattnaik from the university of nebraska, l...19 20 nov2018. visit of prof asit pattnaik from the university of nebraska, l...
19 20 nov2018. visit of prof asit pattnaik from the university of nebraska, l...
 
D covid v3a
D covid v3aD covid v3a
D covid v3a
 
Immunology and Detection of Acute HIV-1 Infection
Immunology and Detection of Acute HIV-1 InfectionImmunology and Detection of Acute HIV-1 Infection
Immunology and Detection of Acute HIV-1 Infection
 
Epidemiological indices afk
Epidemiological indices   afkEpidemiological indices   afk
Epidemiological indices afk
 
Molecular and Clinical Pharmacokinetics of NNRTI Regimens
Molecular and Clinical Pharmacokinetics of NNRTI RegimensMolecular and Clinical Pharmacokinetics of NNRTI Regimens
Molecular and Clinical Pharmacokinetics of NNRTI Regimens
 

Viewers also liked

Chiara Veninata - Il contributo dell'Archivio centrale dello Stato al web of ...
Chiara Veninata - Il contributo dell'Archivio centrale dello Stato al web of ...Chiara Veninata - Il contributo dell'Archivio centrale dello Stato al web of ...
Chiara Veninata - Il contributo dell'Archivio centrale dello Stato al web of ...
International Open Data Day Italia
 
Pasamos lista, como cada día, para
Pasamos lista, como cada día, paraPasamos lista, como cada día, para
Pasamos lista, como cada día, para
sancristobalitos
 
Proyecto "Cuerpos Geométricos"
Proyecto "Cuerpos Geométricos"Proyecto "Cuerpos Geométricos"
Proyecto "Cuerpos Geométricos"
cayeanaamancay
 
отпуск без сохранения заработной платы
отпуск без сохранения заработной платыотпуск без сохранения заработной платы
отпуск без сохранения заработной платы
Светлана Хропова
 
Passport applicationform main_english_v2.0
Passport applicationform main_english_v2.0Passport applicationform main_english_v2.0
Passport applicationform main_english_v2.0
sudhakarritu
 
inal_draft_file
inal_draft_fileinal_draft_file
inal_draft_file
SS Free
 
Matriz de valoración del portafolio interactivo digital –pid y planificador d...
Matriz de valoración del portafolio interactivo digital –pid y planificador d...Matriz de valoración del portafolio interactivo digital –pid y planificador d...
Matriz de valoración del portafolio interactivo digital –pid y planificador d...
fabyjulian
 
Sosiale medier for bedrifter!
Sosiale medier for bedrifter!Sosiale medier for bedrifter!
Sosiale medier for bedrifter!
Jimmy Mir
 
Podcastock 2014 WoodStreamのデジタル生活 公開収録 本当は楽しいマイクロソフトのテクノロジー
Podcastock 2014 WoodStreamのデジタル生活 公開収録 本当は楽しいマイクロソフトのテクノロジーPodcastock 2014 WoodStreamのデジタル生活 公開収録 本当は楽しいマイクロソフトのテクノロジー
Podcastock 2014 WoodStreamのデジタル生活 公開収録 本当は楽しいマイクロソフトのテクノロジー
Tomokazu Kizawa
 

Viewers also liked (18)

Seminario#3 Seo_backstage
Seminario#3 Seo_backstageSeminario#3 Seo_backstage
Seminario#3 Seo_backstage
 
Erica
EricaErica
Erica
 
Chiara Veninata - Il contributo dell'Archivio centrale dello Stato al web of ...
Chiara Veninata - Il contributo dell'Archivio centrale dello Stato al web of ...Chiara Veninata - Il contributo dell'Archivio centrale dello Stato al web of ...
Chiara Veninata - Il contributo dell'Archivio centrale dello Stato al web of ...
 
Final portfolio
Final portfolioFinal portfolio
Final portfolio
 
Pasamos lista, como cada día, para
Pasamos lista, como cada día, paraPasamos lista, como cada día, para
Pasamos lista, como cada día, para
 
Proyecto "Cuerpos Geométricos"
Proyecto "Cuerpos Geométricos"Proyecto "Cuerpos Geométricos"
Proyecto "Cuerpos Geométricos"
 
B2 - Integrating on-premises workloads with AWS
B2 - Integrating on-premises workloads with AWSB2 - Integrating on-premises workloads with AWS
B2 - Integrating on-premises workloads with AWS
 
Ιουστινιανός και Αγια-Σοφιά
Ιουστινιανός και Αγια-ΣοφιάΙουστινιανός και Αγια-Σοφιά
Ιουστινιανός και Αγια-Σοφιά
 
'द वैदिक टाइम्स' भारत का सर्वश्रेष्ठ धार्मिक एवं ज्ञानवर्धक समाचार-पत्र अंक ज...
'द वैदिक टाइम्स' भारत का सर्वश्रेष्ठ धार्मिक एवं ज्ञानवर्धक समाचार-पत्र अंक ज...'द वैदिक टाइम्स' भारत का सर्वश्रेष्ठ धार्मिक एवं ज्ञानवर्धक समाचार-पत्र अंक ज...
'द वैदिक टाइम्स' भारत का सर्वश्रेष्ठ धार्मिक एवं ज्ञानवर्धक समाचार-पत्र अंक ज...
 
WITS case study
WITS case studyWITS case study
WITS case study
 
отпуск без сохранения заработной платы
отпуск без сохранения заработной платыотпуск без сохранения заработной платы
отпуск без сохранения заработной платы
 
Passport applicationform main_english_v2.0
Passport applicationform main_english_v2.0Passport applicationform main_english_v2.0
Passport applicationform main_english_v2.0
 
inal_draft_file
inal_draft_fileinal_draft_file
inal_draft_file
 
Matriz de valoración del portafolio interactivo digital –pid y planificador d...
Matriz de valoración del portafolio interactivo digital –pid y planificador d...Matriz de valoración del portafolio interactivo digital –pid y planificador d...
Matriz de valoración del portafolio interactivo digital –pid y planificador d...
 
Sosiale medier for bedrifter!
Sosiale medier for bedrifter!Sosiale medier for bedrifter!
Sosiale medier for bedrifter!
 
Назва презентації
Назва презентаціїНазва презентації
Назва презентації
 
90년 긴 역사를 자랑하는 글로벌 기업, AIA생명을 소개합니다!
90년 긴 역사를 자랑하는 글로벌 기업, AIA생명을 소개합니다!  90년 긴 역사를 자랑하는 글로벌 기업, AIA생명을 소개합니다!
90년 긴 역사를 자랑하는 글로벌 기업, AIA생명을 소개합니다!
 
Podcastock 2014 WoodStreamのデジタル生活 公開収録 本当は楽しいマイクロソフトのテクノロジー
Podcastock 2014 WoodStreamのデジタル生活 公開収録 本当は楽しいマイクロソフトのテクノロジーPodcastock 2014 WoodStreamのデジタル生活 公開収録 本当は楽しいマイクロソフトのテクノロジー
Podcastock 2014 WoodStreamのデジタル生活 公開収録 本当は楽しいマイクロソフトのテクノロジー
 

Similar to Emmanuel ngabirano

PlosOne_EarlyOutcomes_RRTBTx.PDF
PlosOne_EarlyOutcomes_RRTBTx.PDFPlosOne_EarlyOutcomes_RRTBTx.PDF
PlosOne_EarlyOutcomes_RRTBTx.PDF
Erika Mohr
 
Omosa-Manyonyi_B002_PLOS ONE_2015
Omosa-Manyonyi_B002_PLOS ONE_2015Omosa-Manyonyi_B002_PLOS ONE_2015
Omosa-Manyonyi_B002_PLOS ONE_2015
Jana Carga
 
Highly active antiretroviral therapy: Incidence of adverse drug reactions
Highly active antiretroviral therapy: Incidence of adverse drug reactionsHighly active antiretroviral therapy: Incidence of adverse drug reactions
Highly active antiretroviral therapy: Incidence of adverse drug reactions
pharmaindexing
 
WelaPatrickMsimanga_VirologyJournal_2015
WelaPatrickMsimanga_VirologyJournal_2015WelaPatrickMsimanga_VirologyJournal_2015
WelaPatrickMsimanga_VirologyJournal_2015
25101917
 
Value of insulin__gh__tnf_r__il_1_ra- as published
Value of insulin__gh__tnf_r__il_1_ra- as publishedValue of insulin__gh__tnf_r__il_1_ra- as published
Value of insulin__gh__tnf_r__il_1_ra- as published
Shendy Sherif
 
LungIndia_2013_30_4_316_120608
LungIndia_2013_30_4_316_120608LungIndia_2013_30_4_316_120608
LungIndia_2013_30_4_316_120608
Dr.Divya Shah
 

Similar to Emmanuel ngabirano (20)

PlosOne_EarlyOutcomes_RRTBTx.PDF
PlosOne_EarlyOutcomes_RRTBTx.PDFPlosOne_EarlyOutcomes_RRTBTx.PDF
PlosOne_EarlyOutcomes_RRTBTx.PDF
 
Clinical presentation and outcomes of HIV positive patients with diagnosis of...
Clinical presentation and outcomes of HIV positive patients with diagnosis of...Clinical presentation and outcomes of HIV positive patients with diagnosis of...
Clinical presentation and outcomes of HIV positive patients with diagnosis of...
 
Omosa-Manyonyi_B002_PLOS ONE_2015
Omosa-Manyonyi_B002_PLOS ONE_2015Omosa-Manyonyi_B002_PLOS ONE_2015
Omosa-Manyonyi_B002_PLOS ONE_2015
 
Can we cure HIV/AIDS?: A 2014 progress report
Can we cure HIV/AIDS?: A 2014 progress reportCan we cure HIV/AIDS?: A 2014 progress report
Can we cure HIV/AIDS?: A 2014 progress report
 
Highly active antiretroviral therapy incidence of adverse drug reactions
Highly active antiretroviral therapy incidence of adverse drug reactionsHighly active antiretroviral therapy incidence of adverse drug reactions
Highly active antiretroviral therapy incidence of adverse drug reactions
 
Highly active antiretroviral therapy: Incidence of adverse drug reactions
Highly active antiretroviral therapy: Incidence of adverse drug reactionsHighly active antiretroviral therapy: Incidence of adverse drug reactions
Highly active antiretroviral therapy: Incidence of adverse drug reactions
 
DGH Lecture Series: Judd Walson
DGH Lecture Series: Judd WalsonDGH Lecture Series: Judd Walson
DGH Lecture Series: Judd Walson
 
WelaPatrickMsimanga_VirologyJournal_2015
WelaPatrickMsimanga_VirologyJournal_2015WelaPatrickMsimanga_VirologyJournal_2015
WelaPatrickMsimanga_VirologyJournal_2015
 
Phyllis J. Kanki, 15+ Years of PEPFAR: Getting to Zero
Phyllis J. Kanki, 15+ Years of PEPFAR: Getting to ZeroPhyllis J. Kanki, 15+ Years of PEPFAR: Getting to Zero
Phyllis J. Kanki, 15+ Years of PEPFAR: Getting to Zero
 
Value of insulin__gh__tnf_r__il_1_ra- as published
Value of insulin__gh__tnf_r__il_1_ra- as publishedValue of insulin__gh__tnf_r__il_1_ra- as published
Value of insulin__gh__tnf_r__il_1_ra- as published
 
Single-Tablet Regimen containing Elvitegravir in an HIV-2 Infected Patient
Single-Tablet Regimen containing Elvitegravir in an HIV-2 Infected PatientSingle-Tablet Regimen containing Elvitegravir in an HIV-2 Infected Patient
Single-Tablet Regimen containing Elvitegravir in an HIV-2 Infected Patient
 
Fungal infections in the ICU
Fungal infections in the ICUFungal infections in the ICU
Fungal infections in the ICU
 
CV 2016
CV 2016CV 2016
CV 2016
 
Key developments in HIV/TB research
Key developments in HIV/TB researchKey developments in HIV/TB research
Key developments in HIV/TB research
 
HIV-1 PATHOGENESIS AND GENETIC FORMS
HIV-1 PATHOGENESIS AND GENETIC FORMSHIV-1 PATHOGENESIS AND GENETIC FORMS
HIV-1 PATHOGENESIS AND GENETIC FORMS
 
add1.pdf
add1.pdfadd1.pdf
add1.pdf
 
Strongyloidiasis after corticosteroid therapy: A case report
Strongyloidiasis after corticosteroid therapy: A case reportStrongyloidiasis after corticosteroid therapy: A case report
Strongyloidiasis after corticosteroid therapy: A case report
 
Candida Score-5.pptx
Candida Score-5.pptxCandida Score-5.pptx
Candida Score-5.pptx
 
LungIndia_2013_30_4_316_120608
LungIndia_2013_30_4_316_120608LungIndia_2013_30_4_316_120608
LungIndia_2013_30_4_316_120608
 
A Clinical Study: Tumour Necrosis Factor Alpha as a Clinical Marker in Malari...
A Clinical Study: Tumour Necrosis Factor Alpha as a Clinical Marker in Malari...A Clinical Study: Tumour Necrosis Factor Alpha as a Clinical Marker in Malari...
A Clinical Study: Tumour Necrosis Factor Alpha as a Clinical Marker in Malari...
 

More from Infectious Diseases Institute (9)

Emmanuel Ngabirano
Emmanuel NgabiranoEmmanuel Ngabirano
Emmanuel Ngabirano
 
Research-Emmanuel Ngabirano
Research-Emmanuel NgabiranoResearch-Emmanuel Ngabirano
Research-Emmanuel Ngabirano
 
Emmanuel ngabirano
Emmanuel ngabiranoEmmanuel ngabirano
Emmanuel ngabirano
 
Emmanuel ngabiranos
Emmanuel ngabiranosEmmanuel ngabiranos
Emmanuel ngabiranos
 
Research
ResearchResearch
Research
 
Emmanuel Ngabirano
Emmanuel NgabiranoEmmanuel Ngabirano
Emmanuel Ngabirano
 
Emmanuel ngabirano
Emmanuel ngabiranoEmmanuel ngabirano
Emmanuel ngabirano
 
Chronic hiv care_art Emmanuel Ngabirano 2011 Correspondence engabirano@idi.co.ug
Chronic hiv care_art Emmanuel Ngabirano 2011 Correspondence engabirano@idi.co.ugChronic hiv care_art Emmanuel Ngabirano 2011 Correspondence engabirano@idi.co.ug
Chronic hiv care_art Emmanuel Ngabirano 2011 Correspondence engabirano@idi.co.ug
 
Emmanuel Ngabirano
Emmanuel NgabiranoEmmanuel Ngabirano
Emmanuel Ngabirano
 

Emmanuel ngabirano

  • 1. The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa Emmanuel Ngabirano,Portsmouth, S.; Napolitano, LA.; Eng, S.; Greenacre, Authors: A.; Kambugu, A.; Wood, R.; Badal-Faesen, S. Year: 2012 Journal: J Int AIDS Soc. Volume: 15 Number: 1 Pages: 2 Month: July Abstract: BACKGROUND: The introduction of C-C chemokine receptor type-5 (CCR5) antagonists as antiretroviral therapy has led to the need to study HIV co-receptor tropism in different HIV-1 subtypes and geographical locations. This study was undertaken to evaluate HIV-1 co- receptor tropism in the developing world where non-B subtypes predominate, in order to assess the therapeutic and prophylactic potential of CCR5 antagonists in these regions. METHODS: HIV-1-infected patients were recruited into this prospective, cross-sectional, epidemiologic study from HIV clinics in South Africa, Uganda and India. Patients were infected with subtypes C (South Africa, India) or A or D (Uganda). HIV-1 subtype and co- receptor tropism were determined and analyzed with disease characteristics, including viral load and CD4(+) and CD8(+) T cell counts. RESULTS: CCR5-tropic (R5) HIV-1 was detected in 96% of treatment-naïve (TN) and treatment-experienced (TE) patients in India, 71% of TE South African patients, and 86% (subtype A/A1) and 71% (subtype D) of TN and TE Ugandan patients. Dual/mixed-tropic HIV-1 was found in 4% of Indian, 25% of South African and 13% (subtype A/A1) and 29% (subtype D) of Ugandan patients. Prior antiretroviral treatment was associated with decreased R5 tropism; however, this decrease was less in subtype C from India (TE: 94%, TN: 97%) than in subtypes A (TE: 59%; TN: 91%) and D (TE: 30%; TN: 79%). R5 virus infection in all three subtypes correlated with higher CD4(+) count. CONCLUSIONS: R5 HIV-1 was predominant in TN individuals with HIV-1 subtypes C, A, and D and TE individuals with subtypes C and A. Higher CD4(+) count correlated with R5 prevalence, while treatment experience was associated with increased non- R5 infection in all subtypes